Dyne Therapeutics (NASDAQ:DYN) Upgraded to “Strong-Buy” at Raymond James

Raymond James upgraded shares of Dyne Therapeutics (NASDAQ:DYN) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Several other equities research analysts have also commented on DYN. Morgan Stanley raised their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Oppenheimer reissued an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, Guggenheim upped their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.42.

Dyne Therapeutics Stock Up 0.5 %

DYN opened at $25.73 on Thursday. The company’s 50-day moving average price is $30.39 and its 200 day moving average price is $35.20. Dyne Therapeutics has a fifty-two week low of $11.51 and a fifty-two week high of $47.45. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of -7.23 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Research analysts anticipate that Dyne Therapeutics will post -3.45 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now directly owns 201,685 shares of the company’s stock, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 180,046 shares of company stock valued at $6,300,265 over the last ninety days. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC lifted its position in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $36,000. US Bancorp DE grew its holdings in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics in the third quarter worth $62,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.